Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The decision was driven by results from the Phase III CAPItello-281 trial,
KIHT can now conduct clinical research for drugs and medical devices, strengthening evidence generation and healthcare innovation
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Indian Pharmacopoeia Commission hosts scientific conclave to brainstorm on strengthening pharmaceutical quality and compliance
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
